Early Detection, Better Direction: Tau Biomarkers and Amyloid-Targeting Therapies (ATTs) in AD

Due to the rising prevalence and significant burden of Alzheimer’s disease there is a critical need for continuing education aimed at bridging existing gaps in clinician knowledge, competence, and performance concerning novel and emerging amyloid-targeting therapies (ATTs), especially in the early symptomatic stages of AD where timely and optimal intervention can significantly alter patient outcomes. By fostering a nuanced understanding of AD neuropathology, biomarker relevance, and the practical application of ATTs, this initiative proposes to equip global dementia specialists, neurologists, geriatricians, and geriatric psychiatrists with the essential knowledge and skills required to improve the diagnostic accuracy and therapeutic management of AD.

In this CMEO Snack entitled, Early Detection, Better Direction: Tau Biomarkers and Amyloid-Targeting Therapies in Alzheimer's Disease, expert faculty will discuss strategies for identifying the neuropathological chances associated with AD, assessing the role of phosphorylated tau biomarkers, evaluating latest data from clinical trials on ATTs, and identifying appropriate patients to ensure timely and optimal management.

Learn More: https://www.cmeoutfitters.com/activit...